Abstract : Aim : The aim of the present study was to assess the changes in bone mineral density and bone turnover markers in long-term SERM. Methods : The study was performed on 25 female outpatients with primary osteoporosis treated at the Osteoporosis Department of Showa University School of Medicine. All patients had been on raloxifene 60 mg/day for ≥ 3 years. The mean patient age was 67.1 years and the women were, on average, 18.4 years postmenopausal. Levels of bone turnover markers urinary naltrexone NTX and bone-speci c alkaline phosphatase BAP and bone mineral density BMD ; front lumbar vertebrae, three proximal femur sites, and two distal radius sites were determined before and then annually after starting raloxifene for a period of 3 years. Results : Over the 3-year treatment period, signi cant decreases were seen in both urinary NTX and BAP levels. Although BMD of the lumbar vertebrae and distal radius was increased over the 3 years after initiation of raloxifene treatment, the difference failed to reach statistical signicance. The BMD of the femoral neck decreased, whereas that of the femoral trochanter and femoral intertrochanter area increased. Conclusions : The selective estrogen receptor modulator raloxifene is suitable for the treatment of osteoporosis in postmenopausal patients because it reduces bone turnover while maintaining adequate bone density.
Introduction
In Japan, osteoporosis can be treated with bisphosphonates, selective estrogen receptor modulators SERMs , parathyroid hormone PTH , or calcitonin. Bisphosphonates improve bone mineral density BMD and inhibit bone resorption. However, there are some limitations associated with their use : patients have to take the drug soon after waking up, they must avoid lying down for at least 30 min, and they need to take the drug with approxi- Original mately 180 mL water. There are no such limitations imposed on the use of SERMs, making these drugs the preferred treatment option for osteoporosis. SERMs have been reported to increase the formation of collagen cross-links and to improve bone mineral properties 1 2 .
However, only postmenopausal women can be administered SERMs, and physicians are required to select other drugs for the treatment of osteoporosis in men or premenopausal women. Compared with bisphosphonates, such as alendronate and risedronate, SERMs only slightly improve markers of bone turnover. In the present study, to evaluate the ef cacy of SERM treatment, we investigated changes in multiple markers of bone turnover, as well as BMD at different sites, over a 3-year period in women who had been on the SERM raloxifene for at least 3 years beginning in 2007.
Methods

Subjects
The subjects of the present study were 25 women who were attending the Osteoporosis Outpatient Unit of Showa University Hospital for the treatment of postmenopausal osteoporosis. All women had been on raloxifene 60.0 mg/day for 3 years. The mean age of the women was 67.1 years range 54-84 years , and they were, on average, 18.4 years postmenopausal range 3-36 years .
Methodology
Markers of bone turnover urinary cross-linked N-terminal telopeptides of type I collagen NTX and bone-speci c alkaline phosphatase BAP and BMD were determined in each patient before and then annually after starting raloxifene treatment. BMD was measured in the anteroposterior lumbar spine, the proximal femur neck, intertrochanter, and trochanter , and the ultradistal radius the ultradistal radius and distal one-third of the radius by dual energy X-ray absorptiometry Discovery A ; Hologic, Bedford, MA, USA .
Statistical analysis
Data are presented as the mean SD. Values obtained prior to initiating treatment were considered as reference baseline values. Differences were analyzed using Student s t-test, with P 0.05 considered signi cant. All analyses were performed using Stat Mate III ver.
3.14 ATMS, Tokyo, Japan .
Ethical considerations
This study was approved by the Ethics Committee of Showa University School of Medicine Approval No. 1169 . All patients provided written informed consent prior to participating in the study.
Results
Markers of bone turnover
Prior to starting raloxifene treatment, mean urinary NTX levels in the 25 women were 61.9 32.6 nmol bone collagen equivalents BCE /mmol creatinine Cr . After 1, 2, and 3 years treatment, urinary NTX levels were 44.3 27.4, 41.7 26.9, and 38.5 17.5 nmol BCE/ mmol Cr, respectively P 0.01, P 0.01, and P 0.001 compared with baseline, respectively . As indicated in Fig Bone mineral density Table 1 There were no significant changes in the BMD of L2-L4 over the 3-year treatment period Fig. 3a . Most importantly, none of the patients experienced any new compression fractures over this time.
In the proximal femur, there were signi cant decreases in the BMD of the femoral neck Fig. 1 . Urinary levels of type I collagen cross-linked N-telopeptides NTX before and after 1, 2, and 3 years of treatment with raloxifene 60.0 mg/day . There was a signi ficant de crease in NTX levels after 1 year, and although there was a tendency for levels to de crease in subsequent years, values were main tained at around 40 bone collagen equivalents BCE / mmol creatinine Cr . Data are the mean SD., P 0.01, P 0.001 compared with baseline before treatment values. 
Discussion
Raloxifene, a SERM, is a member of the benzothiophene family that does not have a steroidal backbone. It inhibits bone resorption without affecting the endometrium and In 2000, the US National Institutes of Health de ned bone strength as 70% BMD and 30% ossein 6 . Bone turnover, microstructure, microfracture, and calci cation are the factors contributing to ossein. Of these, bone turnover is the most easily measured in clinical practice using markers of bone turnover 7 8 , such as NTX levels in the blood and urine, BAP, tartrate-resistant acid phosphatase-5b, and N-propeptide of type I procollagen. Undercarboxylated osteocalcin ucOC is another marker of bone turnover that can be used as an index of suf cient vitamin K levels in the blood. If blood ucOC levels are high, vitamin K 2 may be administered. Furthermore, levels of pentosidine or homocysteine can be used as predictors of vertebral fractures 9 . Although these measures provide clinically important information, they are currently not covered by osteoporosis insurance in Japan, which is an issue that needs to be resolved.
In the present study, raloxifene decreased NTX by 28% over the course of 1 year. In another study, we found that alendronate decreased NTX by 66% over the course of 1 year 10 . In the present study, raloxifene signi cantly decreased both urinary NTX a marker of bone resorption and BAP a marker of bone formation , and inhibited bone turnover.
We did not observe atypical femur fractures 11 12 or jaw osteonecrosis 13 , which have been reported previously as complications associated with the use of bisphosphonates, and this may be due to the lower potency of raloxifene. If signi cant inhibition of bone resorption markers is necessary, then bisphosphonates are the better choice ; however, in patients undergoing dental treatment, those exhibiting only slightly enhanced levels of bone resorption markers, or in those who are recovering from fractures i.e. those in whom bone turnover should not be excessively inhibited , it is preferable to use SERMs.
There were no significant decreases in the BMD of the lumbar vertebrae or radius.
However, there was a decrease in the BMD of the femoral neck and an increase in the BMD of the femoral trochanter. The femoral trochanter has more spongy bone than the femoral neck 14 , which may explain the increase in BMD in the trochanter over the course of drug treatment. According to a bridging study of raloxifene conducted in Japan 4 , the BMD of the lumbar vertebrae in the raloxifene-treated group was signi cantly higher than that of the placebo-treated group after 24 weeks, with the former group also exhibiting a signi cantly higher mean increase in BMD after 1 year of treatment 3.5% . In the multiple outcomes of raloxifene evaluation MORE trial, the BMD of the lumbar vertebrae and femoral neck increased by 2.6% and 1.3%, respectively, signi cantly higher than that in the placebo-treated group 15 . No signi cant differences of the BMD of the lumbar vertebrae were observed between before administration and after 3 years in the present study, although there was a tendency for the BMD of the lumbar vertebrae to increase with treatment. The radius is not a weight-bearing bone and is not easily affected by mechanical stress. Wiping the oor with hands is a good exercise for the radius ; however, modern lifestyles offer few opportunities to perform such tasks. We recommend that people perform intentional weight-bearing exercises for the radius e.g. wall-pushing exercise and femoral neck e.g. standing on one leg with the eyes open 16 , both of which contain cortical bone.
In conclusion, in the present study we examined the effects of raloxifene, a SERM, on BMD and markers of bone turnover over a 3-year period. During this time, there was a signi cant decrease in markers of bone turnover. Although there was a tendency for increased BMD of the lumbar vertebrae over the same period, the differences failed to reach statistical signi cance. Thus, raloxifene appears to be suitable for use in postmenopausal women in whom bone turnover needs to be decreased gradually while BMD is maintained.
